Literature DB >> 10199788

Characterization of Prophet of Pit-1 gene expression in normal pituitary and pituitary adenomas in humans.

Y Nakamura1, T Usui, H Mizuta, H Murabe, S Muro, M Suda, K Tanaka, I Tanaka, A Shimatsu, K Nakao.   

Abstract

Prophet of Pit-1 (Prop-1), which is a paired-like homeodomain transcription factor, is capable of binding to sites in an early enhancer of the Pit-1 gene and regulating its expression. According to a previous report, Prop-1 messenger RNA (mRNA) is expressed in the developing pituitary gland before Pit-1 mRNA expression and maximum expression are observed at e 12.0. After e 14.5, Prop-1 mRNA expression rapidly decreases, and only trace amounts of mRNA are detectable in adult mouse pituitary. Human Pit-1 is expressed considerably, not only in normal adult pituitary but also in pituitary adenomas, so we studied human Prop-1 gene expression in adult pituitary and pituitary adenomas. We also cloned human Prop-1 complementary DNA (cDNA) and sequenced the Prop-1 cDNAs in pituitary adenomas. The amino acid sequence of human Prop-1 cDNA that we cloned was identical to that of the previously reported sequence, except Thr substituted at codon 142 instead of Ala. This amino acid substitution is considered to be a polymorphism because it did not alter transcriptional activity, and 7 of 28 alleles were Ala. Human Prop-1 transcript was detected in normal adult pituitary, by Northern blot analysis, and in all pituitary adenomas examined by RT-PCR analysis. The expression of human Prop-1 in pituitary adenomas was confirmed by in situ hybridization in one of the somatotroph adenomas. The sequence analysis of human Prop-1 cDNAs in these pituitary adenomas revealed that there were no mutations, except 5 silent nucleic acid substitutions, suggesting that mutations of Prop-1 gene do not represent a frequent mechanism of human pituitary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10199788     DOI: 10.1210/jcem.84.4.5630

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Clinical and molecular features of a TSH-secreting pituitary microadenoma.

Authors:  Takeshi Usui; Shoichiro Izawa; Toshiaki Sano; Tetsuya Tagami; Daisuke Nagata; Akira Shimatsu; Jun A Takahashi; Mitsuhide Naruse
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Immunonegative "null cell" adenomas and gonadotropin (Gn) subunit (SUs) immunopositive adenomas share frequent expression of multiple transcription factors.

Authors:  Yudo Ishii; Masanori Suzuki; Susumu Takekoshi; Noboru Egashira; Michio Yamazaki; Shunsuke Miyai; Naoko Sanno; Akira Teramoto; Robert Yoshiyuki Osamura
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

Review 3.  Molecular pathology of pituitary adenomas.

Authors:  R V Lloyd
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

4.  Transcript abundance in mouse pituitaries with altered growth hormone expression quantified by reverse transcriptase polymerase chain reaction implicates transcription factor Zn-16 in gene regulation in vivo.

Authors:  Patrick W Wojtkiewicz; Carol J Phelps; David L Hurley
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

5.  No mutations in TPIT, a corticotroph-specific gene, in human tumoral pituitary ACTH-secreting cells.

Authors:  L G Bucciarelli; F Pecori Giraldi; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

Review 6.  Impact of Growth Hormone-Related Mutations on Mammalian Aging.

Authors:  Andrzej Bartke; Nana Quainoo
Journal:  Front Genet       Date:  2018-11-27       Impact factor: 4.599

7.  Comparative genomics reveals functional transcriptional control sequences in the Prop1 gene.

Authors:  Robert D Ward; Shannon W Davis; Minchul Cho; Constance Esposito; Robert H Lyons; Jan-Fang Cheng; Edward M Rubin; Simon J Rhodes; Lori T Raetzman; Timothy P L Smith; Sally A Camper
Journal:  Mamm Genome       Date:  2007-06-08       Impact factor: 2.957

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.